Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) without an identifiable cause. If not treated after diagnosis, the average life expectancy is 3–5 years. Currently approved drugs for the treatment of IPF are Pirfenidone and Nintedanib, as antifibrotic dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xudan, Xu, Zhihao, Hu, Songhua, Shen, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973527/
https://www.ncbi.nlm.nih.gov/pubmed/36865908
http://dx.doi.org/10.3389/fphar.2023.1111393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973527/
https://www.ncbi.nlm.nih.gov/pubmed/36865908
http://dx.doi.org/10.3389/fphar.2023.1111393

Ejemplares similares